Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.53T
24h Vol:
$5.13B
Dominance:
MSFT:5.13%
Stocklytics Platform
BETA
Instrument logo  ASMB

Assembly Biosciences Inc

ASMB
69 / 100
High Growth
$11.58arrow_drop_up2.11%$0.24

Performance History

Stocklytics logo
Key Stats
Open$11.43
Prev. Close$11.45
EPS-17.16
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap62174725.20
PE Ratio-
LOWHIGH
Day Range11.05
11.50
52 Week Range7.68
20.04
Ratios
P/B Ratio1.49
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %21.95%
EBITDA Margin %-
ROE %-100.84%
EPS-17.16

Score Breakdown

69vs 53. Market Avg.

All Score 69 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

ASMBMARKET
Value5039
Quality3740
Ownership2019
Growth9446
Dividends-37
check_circle

Assembly Biosciences Inc's Price growth average in the last 3 years of 219.62% is great compared to market average of 5.99%. This indicates ASMB could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$768.20
24H (%)arrow_drop_down-0.48%
24H ($)-$3.71
MARKET CAP$730.18B
PRICE$522.56
24H (%)arrow_drop_down-0.52%
24H ($)-$2.76
MARKET CAP$483.11B
PRICE$160.63
24H (%)arrow_drop_down-0.09%
24H ($)-$0.15
MARKET CAP$387.08B
PRICE$128.83
24H (%)-0.00%
24H ($)-$0.01
MARKET CAP$326.55B

About Assembly Biosciences Inc (ASMB)

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jason A. Okazaki
Headquarters
South San Francisco
Employees
70
Exchange
NASDAQ
add Assembly Biosciences Inc to watchlist

Keep an eye on Assembly Biosciences Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Assembly Biosciences Inc's (ASMB) price per share?

The current price per share for Assembly Biosciences Inc (ASMB) is $12.24. The stock has seen a price change of $0.66 recently, indicating a 5.7% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Assembly Biosciences Inc (ASMB)?

For Assembly Biosciences Inc (ASMB), the 52-week high is $20.04, which is 63.73% from the current price. The 52-week low is $7.68, the current price is 59.38% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Assembly Biosciences Inc (ASMB) a growth stock?

Assembly Biosciences Inc (ASMB) has shown an average price growth of 219.62% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Assembly Biosciences Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Assembly Biosciences Inc (ASMB) stock price performance year to date (YTD)?

As of the latest data, Assembly Biosciences Inc (ASMB) has a year-to-date price change of .

question_mark
Is Assembly Biosciences Inc (ASMB) a profitable company?

Assembly Biosciences Inc (ASMB) has a net income of -$72.66M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$75.07M. Furthermore, the EBITDA is -$75.29M.

question_mark
What is the market capitalization of Assembly Biosciences Inc (ASMB)?

Assembly Biosciences Inc (ASMB) has a market capitalization of $67.11M. The average daily trading volume is 19.88K, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.